Back
ESC Premium Access

Secondary prevention in 2030: will antiplatelets or anticoagulants prevail?

Session: Antithrombotic therapy for coronary artery disease: opportunities and challenges
Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)
Speaker: Professor D. Angiolillo (Jacksonville, US)
Event: ESC Congress 2019

Congress Presentation

About the speaker

Professor Dominick Joseph Angiolillo

University of Florida College of Medicine – Jacksonville, Jacksonville (United States of America)
27 presentations
2 followers

3 more presentations in this session

State of the Art - New options in antithrombotic therapy for coronary artery disease

Speaker: Professor K. Newby (Durham, US)

Access
Slides
Video
Thumbnail

Atherothrombotic risk and outcomes following guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome:a post-hoc analysis of the TROPICAL-ACS trial

Speaker: Assistant Professor K. Rizas (Munich, DE)

Access
Abstract
Slides
Video
Thumbnail

Frequency, management and outcomes of patients with stable coronary artery disease eligible for COMPASS. An analysis of the CLARIFY registry.

Speaker: Doctor E. Sorbets (Paris, FR)

Access
Abstract
Slides
Video
Thumbnail

Access the full session

Antithrombotic therapy for coronary artery disease: opportunities and challenges

Speakers: Professor D. Angiolillo, Professor K. Newby, Assistant Professor K. Rizas, Doctor E. Sorbets
Access
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb